179 related articles for article (PubMed ID: 38633593)
1. Expanding the Chemical Space of Transforming Growth Factor-β (TGFβ) Receptor Type II Degraders with 3,4-Disubstituted Indole Derivatives.
Längle D; Wojtowicz-Piotrowski S; Priegann T; Keller N; Wesseler F; Reckzeh ES; Steffens K; Grathwol C; Lemke J; Flasshoff M; Näther C; Jonson AC; Link A; Koch O; Di Guglielmo GM; Schade D
ACS Pharmacol Transl Sci; 2024 Apr; 7(4):1069-1085. PubMed ID: 38633593
[TBL] [Abstract][Full Text] [Related]
2. TbetaRI/Alk5-independent TbetaRII signaling to ERK1/2 in human skin cells according to distinct levels of TbetaRII expression.
Bandyopadhyay B; Han A; Dai J; Fan J; Li Y; Chen M; Woodley DT; Li W
J Cell Sci; 2011 Jan; 124(Pt 1):19-24. PubMed ID: 21172820
[TBL] [Abstract][Full Text] [Related]
3. TGF beta (transforming growth factor beta) receptor type III directs clathrin-mediated endocytosis of TGF beta receptor types I and II.
McLean S; Di Guglielmo GM
Biochem J; 2010 Jul; 429(1):137-45. PubMed ID: 20406198
[TBL] [Abstract][Full Text] [Related]
4. Assembly of TbetaRI:TbetaRII:TGFbeta ternary complex in vitro with receptor extracellular domains is cooperative and isoform-dependent.
Zúñiga JE; Groppe JC; Cui Y; Hinck CS; Contreras-Shannon V; Pakhomova ON; Yang J; Tang Y; Mendoza V; López-Casillas F; Sun L; Hinck AP
J Mol Biol; 2005 Dec; 354(5):1052-68. PubMed ID: 16289576
[TBL] [Abstract][Full Text] [Related]
5. De-ubiquitinating enzyme, USP11, promotes transforming growth factor β-1 signaling through stabilization of transforming growth factor β receptor II.
Jacko AM; Nan L; Li S; Tan J; Zhao J; Kass DJ; Zhao Y
Cell Death Dis; 2016 Nov; 7(11):e2474. PubMed ID: 27853171
[TBL] [Abstract][Full Text] [Related]
6. Targeting all transforming growth factor-β isoforms with an Fc chimeric receptor impairs tumor growth and angiogenesis of oral squamous cell cancer.
Takahashi K; Akatsu Y; Podyma-Inoue KA; Matsumoto T; Takahashi H; Yoshimatsu Y; Koinuma D; Shirouzu M; Miyazono K; Watabe T
J Biol Chem; 2020 Sep; 295(36):12559-12572. PubMed ID: 32631954
[TBL] [Abstract][Full Text] [Related]
7. Extracellular and cytoplasmic domains of endoglin interact with the transforming growth factor-beta receptors I and II.
Guerrero-Esteo M; Sanchez-Elsner T; Letamendia A; Bernabeu C
J Biol Chem; 2002 Aug; 277(32):29197-209. PubMed ID: 12015308
[TBL] [Abstract][Full Text] [Related]
8. Progression of melanoma is suppressed by targeting all transforming growth factor‑β isoforms with an Fc chimeric receptor.
Kodama S; Podyma-Inoue KΑ; Uchihashi T; Kurioka K; Takahashi H; Sugauchi A; Takahashi K; Inubushi T; Kogo M; Tanaka S; Watabe T
Oncol Rep; 2021 Sep; 46(3):. PubMed ID: 34296292
[TBL] [Abstract][Full Text] [Related]
9. βarrestin2 interacts with TβRII to regulate Smad-dependent and Smad-independent signal transduction.
McLean S; Bhattacharya M; Di Guglielmo GM
Cell Signal; 2013 Jan; 25(1):319-31. PubMed ID: 23069267
[TBL] [Abstract][Full Text] [Related]
10. CCN2/CTGF increases expression of miR-302 microRNAs, which target the TGFβ type II receptor with implications for nephropathic cell phenotypes.
Faherty N; Curran SP; O'Donovan H; Martin F; Godson C; Brazil DP; Crean JK
J Cell Sci; 2012 Dec; 125(Pt 23):5621-9. PubMed ID: 22976296
[TBL] [Abstract][Full Text] [Related]
11. An efficient method for expression in Escherichia coli and purification of the extracellular ligand binding domain of the human TGFbeta type II receptor.
Gasparian ME; Elistratov PA; Yakimov SA; Dolgikh DA; Kirpichnikov MP
J Biotechnol; 2010 Jul; 148(2-3):113-8. PubMed ID: 20451568
[TBL] [Abstract][Full Text] [Related]
12. Transforming the TGFbeta pathway: convergence of distinct lead generation strategies on a novel kinase pharmacophore for TbetaRI (ALK5).
Singh J; Ling LE; Sawyer JS; Lee WC; Zhang F; Yingling JM
Curr Opin Drug Discov Devel; 2004 Jul; 7(4):437-45. PubMed ID: 15338953
[TBL] [Abstract][Full Text] [Related]
13. Interaction of TGFβ3 ligand with its receptors type II (TβRII) and type I (TβRI): A unique mechanism of protein-protein association.
Dawn A; Khatri KS; Karmakar S; Deep S
Biochim Biophys Acta Proteins Proteom; 2020 Nov; 1868(11):140485. PubMed ID: 32652126
[TBL] [Abstract][Full Text] [Related]
14. Type I transforming growth factor beta receptor binds to and activates phosphatidylinositol 3-kinase.
Yi JY; Shin I; Arteaga CL
J Biol Chem; 2005 Mar; 280(11):10870-6. PubMed ID: 15657037
[TBL] [Abstract][Full Text] [Related]
15. Attenuated transforming growth factor beta signaling promotes nuclear factor-kappaB activation in head and neck cancer.
Cohen J; Chen Z; Lu SL; Yang XP; Arun P; Ehsanian R; Brown MS; Lu H; Yan B; Diallo O; Wang XJ; Van Waes C
Cancer Res; 2009 Apr; 69(8):3415-24. PubMed ID: 19351843
[TBL] [Abstract][Full Text] [Related]
16. A pivotal role for the transmembrane domain in transforming growth factor-beta receptor activation.
Zhu HJ; Sizeland AM
J Biol Chem; 1999 Apr; 274(17):11773-81. PubMed ID: 10206994
[TBL] [Abstract][Full Text] [Related]
17. Three key residues underlie the differential affinity of the TGFbeta isoforms for the TGFbeta type II receptor.
De Crescenzo G; Hinck CS; Shu Z; Zúñiga J; Yang J; Tang Y; Baardsnes J; Mendoza V; Sun L; López-Casillas F; O'Connor-McCourt M; Hinck AP
J Mol Biol; 2006 Jan; 355(1):47-62. PubMed ID: 16300789
[TBL] [Abstract][Full Text] [Related]
18. TGFbeta Type III and TGFbeta Type II receptors have distinct activities during epithelial-mesenchymal cell transformation in the embryonic heart.
Boyer AS; Runyan RB
Dev Dyn; 2001 Aug; 221(4):454-9. PubMed ID: 11500982
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of transforming growth factor-β signals suppresses tumor formation by regulation of tumor microenvironment networks.
Tokizaki S; Podyma-Inoue KA; Matsumoto T; Takahashi K; Kobayashi M; Ibi H; Uchida S; Iwabuchi S; Harada H; Hashimoto S; Miyazono K; Shirouzu M; Watabe T
Cancer Sci; 2024 Jan; 115(1):211-226. PubMed ID: 37972575
[TBL] [Abstract][Full Text] [Related]
20. Cell-specificity of transforming growth factor-beta response is dictated by receptor bioavailability.
Suszko MI; Woodruff TK
J Mol Endocrinol; 2006 Jun; 36(3):591-600. PubMed ID: 16720726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
